Phaseline

Companies › ARCE Therapeutics

ARCE Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ARD103
anti-CLL-1 CAR-T cell therapy
CLEC12APhase 1Acute Myeloid Leukemia, in RelapseOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06680752ARD103Phase 1Acute Myeloid Leukemia, in RelapseHematologyOct 2028

Targets

CLEC12A (1)

Companies with the same targets

Celyad Oncology

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.